Plant Name: Rauvolfia verticillata
Taxonomic Information:
Plant ID: NPO18714
Plant Latin Name: Rauvolfia verticillata
Taxonomy Genus: Rauvolfia
Taxonomy Family: Apocynaceae
Plant External Links:
NCBI TaxonomyDB:
329875
Plant-of-the-World-Online:
81667-1
Used in Medicines:
Country/Region:
Malaysia; Indonesia; Vietnam; ThailandTraditional Medicine System:
Geographical Distribution:
Myanmar; Philippines; Indonesia; India; Cambodia; Malaysia; Vietnam; China; Laos; Sri Lanka; Thailand; Taiwan
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRA2C; ADRA2A; ADRA2B; | |
| NPSR1; | |
| CA7; CA9; CA13; | |
| HIF1A; NFKB1; | |
| MAPT; LMNA; RAB9A; NPC1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.150E-12 | 1.339E-07 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.023E-10 | 2.203E-06 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 5.662E-10 | 4.110E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 2.264E-09 | 7.041E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 2.264E-09 | 7.041E-06 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.264E-09 | 7.041E-06 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 3.162E-08 | 5.297E-05 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 3.162E-08 | 5.297E-05 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.982E-08 | 8.684E-05 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.240E-07 | 1.588E-04 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.559E-07 | 2.787E-04 | CA13, CA7, CA9 |
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 6.395E-07 | 5.802E-04 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 9.919E-07 | 8.307E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.792E-06 | 1.301E-03 | CYP1A2, CYP2C9, CYP2D6, CYP3A4, NPC1 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 2.186E-06 | 1.442E-03 | CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 2.581E-06 | 1.606E-03 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 3.332E-06 | 1.860E-03 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 3.332E-06 | 1.860E-03 | CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.971E-06 | 2.109E-03 | CA13, CA7, CA9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.095E-06 | 2.123E-03 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.333E-06 | 3.327E-03 | CA13, CA7, CA9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 9.921E-06 | 4.236E-03 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | Unclassified; | GO:0019229; regulation of vasoconstriction | 1.878E-05 | 7.181E-03 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0019896; axonal transport of mitochondrion | 2.615E-05 | 9.335E-03 | HIF1A, MAPT |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 2.984E-07 | 9.874E-06 | CYP2C9, CYP2D6, CYP1A2, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.750E-07 | 9.874E-06 | CYP2C9, CYP2D6, CYP1A2, CYP3A4 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.443E-07 | 9.874E-06 | CA7, CA9, CA13 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.839E-06 | 3.631E-05 | CYP2C9, CYP1A2, CYP3A4 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.157E-05 | 3.407E-04 | CYP2C9, CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 4.334E-05 | 5.706E-04 | CYP2C9, CYP1A2, CYP3A4 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 3.568E-04 | 4.026E-03 | ADRA2C, ADRA2B, ADRA2A |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.548E-03 | 1.358E-02 | ADRA2C, ADRA2B, ADRA2A |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.093E-03 | 1.079E-02 | CYP1A2, CYP3A4 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 3.396E-03 | 2.683E-02 | HIF1A, NFKB1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; MAPT; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2A; ADRA2C; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA2C; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
